LXN and prostate cancer: Antitumour proteins such as latexin, glutathione S-transferase P, Rho GDP-dissociation inhibitor 1, and serpin B5 were reduced in their expression in PC3 prostate cancer cells (Table 2), in agreement with the previous studies [41–44].